1. Canada Stocks

  2. •

    Commercial services

  3. •

    Miscellaneous commercial services
ASEP Medical Holdings Inc

ASEP Medical Holdings Inc

0.05
EUR
0.00
(0.00%)
-0.34EPS
1.09MMarket Cap
ASEP Medical Holdings Inc
GETTEX:JJ80
(Gettex)

Recent

price

0.05

P/E

ratio

- -

div

yld

- -

ROIC.AI

2021
2022
2023
2024
2025
TTM
CAD
- -
- -
- -
- -
0.03
0.03
Revenue per Share
-0.39
-0.81
-1.32
- -
-0.48
-0.34
Basic EPS, GAAP
-0.22
-0.64
-0.44
- -
-0.12
-0.1
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
Dividend per Share
3.25
2.49
1.7
- -
0.21
0.19
Book Value per Share
-1.18
-1.31
-1.39
- -
-0.39
-0.22
Tangible Book Value per Share
6
6
6
8
10
12
Basic Weighted Avg Shares
- -
- -
- -
- -
- -
- -
Sales/Revenue/Turnover
- -
- -
-36,524.42
- -
-761.37
-635.97
Operating Margin (%)
- -
1
1
- -
1
1
Depreciation Expense
-2
-5
-8
- -
-5
-4
Net Income, GAAP
- -
- -
- -
- -
- -
- -
Effective Tax Rate (%)
- -
- -
-38,918.3
- -
-1,459.7
-1,223.05
Profit Margin (%)
6
3
-1
- -
-2
-2
Working Capital
- -
- -
- -
- -
- -
- -
LT Debt
31
27
23
- -
4
5
Total Equity
- -
- -
- -
- -
- -
- -
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
-26.83
-58.6
- -
- -
- -
Return on Common Equity (%)

Capital Structure

CAD

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
ST Debt
- -
- -
- -
LT Borrowings
- -
- -
- -
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
11
11
16
Market Capitalization
3
3
2

Working Capital

CAD

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
Total Current Assets
- -
- -
- -
Cash, Cash Equivalents & STI
- -
- -
- -
Accounts Receivable, Net
- -
- -
- -
Inventories
- -
- -
- -
Total Current Liabilities
2
3
2
Payables & Accruals
2
2
2
ST Debt
- -
- -
- -
Deferred Revenue
- -
- -
- -

Growth Rates

CAD

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
- -
- -
Free Cash Flow
- -
- -
- -
Net Income, GAAP
- -
- -
- -
Sales/Revenue/Turnover
- -
- -
- -
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

CAD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -

Quarterly Earnings Per Share

CAD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
-0.1
-0.15
-0.1
- -
- -
2025
- -
- -
-0.04
-0.25
-0.48
2026
-0.02
-0.04
- -
- -
- -

Quarterly Dividends Per Share

CAD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -
Similar Companies
PayPal Holdings, Inc. (NASDAQ:PYPL)
Shopify Inc. (NASDAQ:SHOP)
Greenland Mines Ltd (NASDAQ:GRML)
Block, Inc. (NYSE:XYZ)
Netcapital Inc. (NASDAQ:NCPL)
Shopify, Inc. Class A (TSX:SHOP)
Business
Asep Medical Holdings Inc (Ticker: SEPSF) is a medical technology company focused on developing innovative diagnostic and monitoring devices for healthcare applications. The company offers the SteriLid™ device, a hands-free eyelid speculum designed to optimize surgical performance during ophthalmic procedures by improving visibility and reducing contamination risks; the NovaEye® GN-100, a portable intraocular pressure measurement tool utilizing advanced tonometry technology for glaucoma assessment; and the CircuLite Intra-Atrial Blood Pump, a miniaturized circulatory support system aimed at treating heart failure patients through minimally invasive implantation. These products target ophthalmologists, cardiologists, and surgical centers, with operations centered in North America and expansion into European markets. Founded in 2015 and headquartered in Toronto, Canada, the company operates without notable subsidiaries or parent relationships. In the latest developments, Asep Medical Holdings Inc advanced its SteriLid™ commercialization efforts through a strategic distribution partnership with K1 Network Inc in 2024, enhancing market penetration in key surgical segments. The company also secured a significant financing round in early 2025, bolstering R&D for next-generation monitoring technologies amid growing demand for infection control solutions. No major acquisitions, name changes, or reorganizations have been reported in the past two years, though operational focus has shifted toward regulatory approvals for international launches.